Non-interventional study evaluates methenamine hippurate for preventing recurrent urinary tract infections, highlighting real-world evidence.
Introduction: Recurrent urinary tract infections (rUTIs) are a significant burden for both affected women and the healthcare system. With the urinary antiseptic drug methenamine hippurate (Cystohipp®), a non-antibiotic, guideline recommended treatment option (AWMF 2024; EAU 2024) for long-term [for full text, please go to the a.m. URL]
No takes yet. Share an insight, caveat, or question.
Wagenlehner et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: